Stockreport

Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer [Yahoo! Finance]

Johnson & Johnson  (JNJ) 
Last johnson & johnson earnings: 4/14 06:31 am Check Earnings Report
US:NYSE Investor Relations: jnj.com
PDF Longer overall survival, progression-free survival and duration of response also observed with subcutaneous amivantamab RARATIN, N.J. June 17, 2024 /PRNewswire/ -- Jo [Read more]